Antibiotic Selection: Cephalexin vs Clindamycin
For most skin and soft tissue infections, cephalexin is the preferred first-line agent over clindamycin, unless the patient has a documented immediate-type penicillin allergy or significant renal impairment requiring dose adjustment. 1
Primary Recommendation for Skin and Soft Tissue Infections
- First-generation cephalosporins like cephalexin should be selected for cellulitis and most staphylococcal/streptococcal skin infections (Grade A-I recommendation), making it superior to clindamycin for routine use 1
- Cephalexin achieves cure rates of 90% or higher for streptococcal and staphylococcal skin infections and is comparable in efficacy to clindamycin 2
- Cephalexin can be dosed twice daily, enhancing medication compliance compared to more frequent dosing regimens 2
Critical Consideration: Penicillin Allergy Status
If Patient Has Immediate-Type Penicillin Allergy:
- Cephalexin must be avoided entirely in patients with immediate-type reactions to amoxicillin, ampicillin, penicillin G, penicillin V, or piperacillin (strong recommendation) 3
- This is due to documented cross-reactivity risk from similar R1 side chain structures between cephalexin and these penicillins 3
- In this scenario, clindamycin becomes the preferred alternative for skin and soft tissue infections 1
If Patient Has Delayed-Type Penicillin Allergy:
- Cephalexin may be considered if the reaction occurred more than 1 year ago (weak recommendation, low-quality evidence) 3
- For recent delayed-type reactions, clindamycin is safer 3
If No Penicillin Allergy:
- Cephalexin is definitively preferred as the first-line agent 1
Renal Function Considerations
For Impaired Renal Function:
- Cephalexin requires dose reduction when creatinine clearance is less than 30 mL/min, as 70-100% of the drug is renally cleared within 6-8 hours 4
- The dose reduction should be proportional to reduced renal function based on creatinine clearance or serum creatinine 4
- Clindamycin does not require renal dose adjustment, making it advantageous in severe renal impairment when dose calculations are complex
For Normal Renal Function:
- Cephalexin is rapidly cleared and achieves excellent tissue concentrations without adjustment 4
Special Clinical Scenarios
Necrotizing Infections:
- For severe group A streptococcal necrotizing infections, parenteral clindamycin plus penicillin is specifically recommended (Grade A-II) 1
- This represents the only scenario where clindamycin is explicitly preferred over cephalosporins in guidelines 1
Animal Bites:
- Neither cephalexin nor clindamycin is appropriate for animal bite infections, as both have poor activity against Pasteurella multocida 1
- Amoxicillin-clavulanate is the treatment of choice 1
Safety and Tolerability Profile
- Cephalexin causes very low incidence of allergy due to its stability and chemical configuration 4
- Cephalexin does not disturb lower bowel flora as it is absorbed high in the intestinal tract 4
- Minor gastrointestinal side effects occur infrequently with cephalexin (reported in approximately 6% of elderly patients with comorbidities) 5
- Both agents have generally mild and infrequent side effects 2
Clinical Algorithm for Decision-Making
Assess for immediate-type penicillin allergy (urticaria, angioedema, anaphylaxis within 1-6 hours of penicillin exposure) 3
- If YES → Choose clindamycin
- If NO → Proceed to step 2
Assess renal function (creatinine clearance) 4
- If CrCl <30 mL/min → Consider clindamycin to avoid complex dose adjustments
- If CrCl ≥30 mL/min → Choose cephalexin
Assess infection type 1
- If necrotizing fasciitis → Choose clindamycin plus penicillin
- If routine cellulitis/skin infection → Choose cephalexin
Common Pitfalls to Avoid
- Do not assume all cephalosporins are safe in penicillin allergy—cephalexin specifically shares side chains with common penicillins and must be avoided in immediate-type reactions 3
- Do not use standard cephalexin dosing in renal impairment—failure to adjust doses when CrCl <30 mL/min can lead to drug accumulation 4
- Do not use cephalexin or clindamycin monotherapy for animal bites—both lack adequate Pasteurella coverage 1